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CASE REPORT
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Early pregnancy of this 31-year-old 3G/3P mother was 
uneventful. At 22 weeks of gestation, reduced am- 
niotic fluid, hyperechogenic bowel and scaphocephaly 
were seen on antenatal ultrasound. The mother was 
referred to the fetal medicine unit at our hospital for 
further evaluation. Amniocentesis revealed a normal 
female karyotype. Maternal TORCH screening showed 
primary cytomegalovirus (CMV) infection with positive 
IgG and IgM titers, and a viral load of 1.2 million DNA 
copies per ml. Amniotic fluid testing confirmed fetal 
infection with positive culture, antigen testing and 
polymerase chain reaction (PCR). 
At 24 weeks of gestation, antenatal ultrasound 
revealed periventricular calcifications in the left cere-
brum. Fetal MRI at that time showed mild ventricu-
lomegaly with septa in the posterior lateral horns 
(Fig. 1) and cysts in the caudothalamic groove. 
4Sagittal and axial T2-weighted MR images at 24 
weeks of gestation showing septa in the posterior 
lateral horns.
Fig. 1
At 34 weeks of gestation, fetal MRI was repeated 
and revealed progressive ventriculomegaly and a small 
cerebellum in addition to the previously described lesi-
ons. No signs of migration abnormalities were seen at 
that point (Fig. 2). 
Fig. 2
5
Axial T2-weighted images at 34 weeks of gestation 
showing progressive ventriculomegaly and cysts in 
the caudothalamic groove.
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The further course of pregnancy was unremarkable, 
fetal weight and head circumferences were normal. 
The mother showed no clinical signs of infection 
during pregnancy. 
At 37 5/7 weeks, a female infant was born by uncom-
plicated spontaneous vaginal delivery following pro-
longed rupture of membranes of 48 hours. Postna-
tal adaptation was uneventful apart from additional 
oxygen administration up to an FiO2 0.4 between 5 
to 10 minutes after birth. Apgar scores were 8, 8 and 
9 at 1, 5 and 10 minutes, respectively, and arterial 
cord pH was 7.23. Body weight was 2900 g (P25-
50), body length was 48 cm (P10-25) and head cir-
cumference was 33 cm (P10-25). Physical examination 
showed multiple petechiae and hepatosplenomegaly 
with the liver edge felt 3 cm and spleen edge 2.5 cm 
below the costal margin. Neurological examination on 
admission revealed no gross abnormalities.
Urine was positive for CMV PCR, CMV culture and anti-
gen testing. On admission, there was a platelet count 
of 65 G/l and a neutrophil count of 3.25 G/l. Cerebral 
US on day one of life showed dilatation of the lateral 
ventricles close to the 97th percentile, bilateral pseu-
docysts in the caudothalamic groove, lenticulostriate 
vasculopathy and a frontal connatal cyst on the left 
side (Fig. 3). Dilatation of the lateral ventricles and the 
size of the pseudocysts were slightly increasing over 
the course of the first 23 days of hospitalization. 
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Fig. 3
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MRI on day 21 of life showed extensive bilateral peri-
sylvian and cerebral polymicrogyria (Fig. 4), reduced 
brain volume, marked ventriculomegaly, multiple 
cerebral and cerebellar calcifications and cysts in the 
caudothalamic groove and in the frontal white matter 
(Fig. 5). 
Coronal and parasagittal cranial ultrasound images 
showing ventriculomegaly, a left-sided frontal cyst in 
the white matter, bilateral cysts in the caudothalamic 
groove, as well as lenticulostriate vasculopathy and 
calcifications.
8Sagittal axial T2-weighted MR images showing exten-
sive polymicrogyria (day of life 21).
Fig. 4
Fig. 5
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Axial and sagittal T2-weighted MR images showing 
ventriculomegaly, cysts in the caudothalamic groove 
and frontal cysts on the left side (day of life 21).
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Otoacoustic emissions failed bilaterally on day of life 
four. In addition, brainstem evoked response audiome-
try (BERA) failed to show response up to sound levels 
of 90 dB, and auditory steady-state response (ASSR) 
testing at 500, 1000, 2000 and 4000 Hz also showed 
no response up to sound levels of 80 dB. Thus, severe 
sensorineural hearing loss (SNHL) was confirmed. 
Ophthalmologic consultation on day three did not 
show any signs of chorioretinitis. Placental histology 
revealed chronic, lymphoplasmatic villitis with immu-
nohistochemical confirmation of CMV bodies.
Antiviral therapy with ganciclovir was started on day 
of life 7 with a dose of 6 mg/kg body weight two 
times a day for 14 days intravenously and then orally 
until day of life 23 (I.e., a corrected gestational age 
of 40 6/7 weeks). Platelet count decreased to 44 G/l 
on day of life 10, and therefore, treatment with gan-
ciclovir was paused for two days until platelet counts 
reached > 100 G/l. Another potential side effect of 
the treatment was neutropenia. Liver and renal blood 
tests, on the other hand, remained normal during the 
antiviral treatment. CMV DNA counts in the blood 
only decreased from 6346 to 5243 copies/ml after 
10 days of treatment. Antigen testing and CMV cul-
ture in the urine remained positive during the entire 
hospital stay. 
Apart from the failed hearing tests, neurological 
assessment was normal for her corrected gestational 
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age. Head growth was normal with head circumfe-
rence of 34.5 cm (P25-50) at discharge.
Antiviral therapy was continued for another 4 weeks 
with oral valganciclovir 16 mg/kg body weight two 
times a day. Over this course of therapy, platelet and 
neutrophil counts were stable and CMV DNA counts 
dropped further to 294 copies/ml. At two months of 
age, BERA and ASSR testing revealed no response up 
to sound levels of 100 dB, confirming the diagnosis of 
severe bilateral SNHL. Support with bilateral hearing 
aids was started and evaluation for possible cochlear 
implants at the age of 6 month is ongoing. Neurologic 
follow-up at four months of age revealed global deve-
lopmental delay (corresponding to an age of about 
two months). In addition, muscular hypotonia, visual 
dysmaturity with intermittent nystagmus and strabis-
mus convergens was present. 
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DISCUSSION Congenital CMV infection is the most common con-
genital infection with a birth prevalence of 0.6 – 0.7% 
in the developed countries, posing a major global bur-
den which exceeds most routinely screened diseases. 
CMV is a neurotropic virus, which establishes lifelong 
latency in infected humans like other herpes viruses. 
The seroprevalence in women of childbearing age in 
Germany is estimated to be 40 to 50%, and the rate 
of CMV acquisition is 1 to 7% per year. The main risk 
factor contributing to CMV acquisition is prolonged 
contact with young children. Maternal infection is 
mostly asymptomatic and fetal transmission can occur 
transplacentally at any gestational age (1, 2).
Primary infection in seronegative mothers occurs in 
1 to 4% of all pregnancies with a high risk for trans-
mission of 30 to 40%. Fortunately, in early pregnancy, 
when infection of the fetus leads to more severe neu-
rologic damage as in our case, intrauterine transmis-
sion rates in maternal primary infection are lower than 
in late pregnancy. In contrast to the presented case, 
more than two-thirds of congenital CMV infections 
occur in seropositive women with secondary infec-
tions (prevalence of reactivation or reinfection with a 
different viral strain estimated at 10 – 30%). The risk 
for transmission in these cases is lower with 1 to 3% 
(1, 2). Approximately 12.7% of all newborn infants 
with congenital CMV infection are symptomatic at 
birth (Table 1).
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Patients with congenital CMV infection are at major 
risk for long-term sequelae. It is the leading cause of 
nonhereditary deafness in children in developed coun-
tries. Hearing loss and motor/cognitive deficits occur 
in about 50% of symptomatic children, whereas vision 
impairment is present in about 22% of the children, 
and 4% of symptomatic children die. Asymptomatic 
newborn infants develop long-term sequelae in 13.5% 
of cases and mortality is close to 0%. However, two-
thirds of infants with long-term sequelae due to con-
genital CMV infection were asymptomatic at birth. 
SNHL, in particular, is known to be progressive (1, 2).
CMV can be found in a wide range of brain cells, hence 
Congenital CMV infection: 
symptoms and laboratory findings 
Petechia Thrombocytopenia
Hepatosplenomegaly Elevated liver enzymes 
Jaundice Conjugated hyperbilirubinaemia
Neurological symptoms 
 Microcephaly 
 Seizures 
 Lethargy, poor suck
Chorioretinitis 
Blueberry muffin rash Anaemia
Intrauterine growth  
restriction (IUGR) 
Hydrops fetalis
14
many structures like the cortex, white matter, germinal 
matrix, basal ganglia, thalamus, brain stem and cere-
bellum can be affected (3, 4). Fetal brain and cortical 
development can grossly be grouped into three diffe-
rent stages: neural proliferation in the ventricular zone 
and neuroblast migration from week 8 to 15, and 20, 
respectively, and neuronal differentiation and organi-
zation which goes on during pregnancy and beyond 
(Fig. 6) (4).
The timing of fetal infection in terms of cerebral 
involvement is crucial. Early fetal infection generally 
leads to more extensive injuries and clinical sequelae. 
Depending of the stage of brain development when 
CMV infection happens, different types of develop-
mental brain malformations occur: infection before 
18 weeks of gestation typically leads to lissencephaly, 
microcephaly, cerebellar hypoplasia and ventriculome-
galy, whereas infection from 18 to 24 weeks leads to 
migrational abnormalities such as polymicrogyria and 
schizencephaly. Periventricular pseudocysts and intra-
ventricular synechiae, cerebellar hypoplasia and mode-
rate ventriculomegaly are common lesions. Finally, 
infections in the third trimester are associated with 
delayed myelination, dysmyelination and white mat-
ter disease. In all stages, calcifications are frequently 
observed (3).
Positive and negative predictive values of cerebral US 
for poor neurological outcome are 66% and 91%, 
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Fig. 6
Fetal brain and cortical development showing the 
three main stages: neural proliferation, neuroblast 
migration and differentiation and organization. 
(adapted from Stanley E, Clinics Dev Medicine, 2010).
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respectively. The weakness of this imaging modality 
lies in its limited ability to visualize the posterior fossa, 
cortical abnormalities, the cerebellum, the subtento-
rial space, sulcation and gyral abnormalities, subtle 
white matter injury and delayed myelination. MRI in 
addition to cerebral US reveals new abnormalities in 
up to 20% of cases and reaches positive and negative 
predictive values of 77% and near 100%, respectively. 
Thus each symptomatic or asymptomatic newborn 
infant with pathologic findings on cerebral US should 
undergo MRI scanning. However normal cerebral US 
imaging and MRI still do not completely rule out long-
term sequelae such as SNHL (3, 5).
Early diagnosis and identification of CNS involvement is 
important for accurate prognosis and decision-making 
regarding postnatal antiviral treatment. A definitive 
diagnosis of congenital infection should be establis-
hed within three weeks after birth, as later diagnosis 
can no longer clearly differentiate between congenital 
and postnatal infection. Detection of CMV in urine or 
saliva is considered the gold standard. CMV PCR has 
displaced „older“ methods such as CMV culture, it is, 
however, much more expensive. Antigen testing has 
a high sensitivity (> 99%) and gives very fast results. 
After confirmation of congenital CMV infection, fur-
ther early evaluation includes full blood count, liver 
function tests and coagulation studies, ophthalmolo-
gical and audiological assessment (6).
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After full evaluation, patients should be allocated to 
one of the following groups: asymptomatic, sympto-
matic, symptomatic with severe focal organ disease, 
or symptomatic with CNS involvement. Severe focal 
disease is defined as severe hepatitis, severe bone mar-
row suppression, colitis or pneumonia. CNS involve-
ment includes pathological findings on neuroimaging, 
microcephaly, SNHL and chorioretinitis (6).
Antiviral treatment should be started within the first 
30 days of life and is clearly recommended in sym-
ptomatic newborn infants with CNS involvement; 
additionally, it can be considered in symptomatic new-
born infants with severe focal disease. In symptomatic 
newborn infants with CNS involvement, ganciclovir 
therapy seems to reduce long-term sequelae: SHNL 
progression and neurodevelopement delay were both 
reduced by 60% within the first year of life (6). Up to 
79% of treated patients were able to maintain normal 
hearing, whereas only 31% of non-treated patients 
did. Only 10 versus 17 developmental milestones were 
not met with therapy versus no therapy. However, 
there is no clear benefit with regards to hepatitis, and 
ganciclovir cannot undo brain lesions, which exist at 
the start of treatment (7).
Current guidelines suggest intravenous treatment 
with ganciclovir for two to three weeks followed by 
oral therapy with valganciclovir to complete 6 weeks 
of therapy in total (6). However, there is emerging 
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evidence that prolonged antiviral treatment up to 6 
months can improve long-term outcomes (7). During 
treatment, weekly full blood count and renal func-
tion tests should be followed to monitor for adverse 
effects (thrombocytopenia, neutropenia, anemia) and 
because ganciclovir is excreted renally. Viral load usu-
ally drops one or two logs during treatment, rises again 
drastically after treatment termination and children 
may excrete CMV in urine for over a year. Long-term 
follow-up includes regular audiology, ophthalmologic 
and neurodevelopment assessments since long-term 
sequelae can worsen or develop de novo over time. 
Current guidelines are summarized in Fig. 7 (6).
Fetal abnormalities in cerebral US, fetal thrombocy-
topenia and IUGR are associated with poor neurode-
velopmental outcome. Odds ratio for poor outcome 
in the presence of fetal cerebral US abnormalities is 
reported as high as 25.5 (8). After birth, microcephaly, 
neuroimaging abnormalities and elevated beta2-
microglobulin levels in cerebrospinal fluid samples 
have been identified as risk factors for poor neurode-
velopmental outcome (9). 
Fig. 7
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Summary of current guidelines on management in 
congenital CMV infection (adapted from Kadambari 
S, Williams EJ, Luck S, et al. Early Human Develop-
ment 2011).
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